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Tangier disease is an autosomal recessive disorder characterized by severe reduction 
in high-density lipoprotein cholesterol and peripheral lipid storage. We describe a family 
with c.5094C > A p.Tyr1698* mutation in the ABCA1 gene, clinically characterized by 
syringomyelic-like anesthesia, demyelinating multineuropathy, and reduction in intraepi-
dermal small fibers innervation. In the proband patient, cardiac involvement determined a 
myocardial infarction; lipid storage was demonstrated in gut, cornea, and aortic wall. The 
reported ABCA1 mutation has never been described before in a Tangier family.
Keywords: tangier, hypoalphalipoproteinemia, neuropathy, demyelinating
INtRoDUCtIoN
Tangier disease (TD) is a rare disorder of high-density lipoprotein (HDL) metabolism with very 
low levels of HDL cholesterol (HDL-C) and apolipoprotein A-I (Apo A-I) and by the accumulation 
of cholesteryl esters (CEs) within macrophage-rich tissues. TD is caused by loss-of-function (LOF) 
mutations in the ATP-binding cassette transporter A1 (ABCA1) gene (1–3), encoding the membrane 
transporter ABCA1. This transporter plays an important role in the efflux of free cholesterol (FC) 
from peripheral cells and its transfer to lipid-poor Apo A-I particles, which represents the first 
stage of reverse cholesterol transport (RCT) pathway (4–8). Therefore, ABCA1 deficiency leads to 
intracellular accumulation of CE, precludes the conversion of the lipid-poor Apo A-I particles into 
pre-β HDL, and promotes a rapid catabolism of the poorly lipidated Apo A-I, mostly by the kidney 
(9). As a consequence, abnormal plasma HDL particles, enlarged orange–yellow tonsils, anemia, 
thrombocytopenia, peripheral neuropathy, and corneal opacifications are the typical clinical features 
of TD patients (10), although presenting with a high degree of variability even in the same family 
(11). TD is often, but not always, associated with an increased risk of coronary artery disease (CAD) 
(10). Nervous system involvement in TD was already documented in 70s and 80s by Dyck et al. (12) 
and Pietrini et al. (13, 14). Rare is the presentation of syringomyelia-like symptoms. Even rarer is a 
demyelinating neuropathy (15–18) and for the majority of the described cases genetic data are not 
available.
Tangier disease is inherited as an autosomal recessive disorder, and affected patients are 
expected to have LOF mutations in both alleles of ABCA1 gene. Heterozygous relatives of TD 
patients may present an intermediate phenotype of low HDL C and approximately 50% reduction 
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in ABCA1-mediated cell cholesterol efflux (19). The human 
ABCA1 gene on chromosome 9q22-q31 contains 50 exons and 
spans 150 kb. At present, over 200 ABCA1 mutations1 have been 
identified in TD patients. They have been reported throughout 
the gene, particularly in exons encoding the extracellular domain 
and the ATP-binding cassettes (nucleotide binding folds) of the 
2261 amino acid protein. Two-third of mutations listed in the 
database are missense mutations while the others are nonsense 
or frameshift mutations. Conversely, those affecting intronic sites 
have been reported only in few cases (20).
In the present article, we describe a novel ABCA1 mutation 
in a family with TD associated with an infrequent neurological 
presentation.
Index patient
A 55-year-old Caucasian female, AC, living in a small town near 
to Matera, presented in October 2013 to Neuromuscular Disease 
Center in Umberto I Hospital, Sapienza University of Rome, 
with a reduction of strength in lower limbs. AC evidenced an 
inexhaustible lateral nystagmus, symmetric facial hypoesthesia 
to pain, bilateral Bell’s phenomenon with upper and lower facial 
hyposthenia, left eyelid myokymia, distal deficit of strength 
in upper limbs, prevailing in the right arm, mild reduction of 
strength in all muscles of lower limbs [4/5 medical research coun-
cil (MRC)], more evident in right dorsal and plantar foot flexors 
(3/5 MRC), and atrophy in intrinsic hands muscles. Suspended 
bilateral hypoesthesia to pain C3-D12 and postural bilateral low 
amplitude hand tremor were also evidenced.
Her medical history was significant for tonsillectomy at age 5 
and adenoidectomy at age 7 for not specified reasons. In 2012, she 
underwent blepharoplasty for bilateral lagophthalmos. In 2013, 
she had a myocardial infarction, treated with double by pass and 
mitral valve replacement with biologic Carpentier valve. In the 
same year, she underwent surgical removal of seven colon polyps. 
In 2002, she was presented with distal symmetrical paresthesia in 
upper limbs; in 2005, she underwent surgery for bilateral carpal 
syndrome. In that circumstance, an axonal motor neuropathy in 
lower limbs was found. In the next 2 years, she noted a progressive 
hypotrophy in the intrinsic muscles of the hands, with distal to 
proximal reduction of strength. A few months later, a bilateral 
sensorineural hearing loss was diagnosed.
AC was admitted in June 2014 for further investigation. 
Cerebral, brainstem, and medullar MRI was effected to rule out 
vascular encephalopathy and syringomyelic cavity. Abdomen 
ultrasound (US) was performed to seek a visceromegaly, as 
described in the literature. She underwent echocardiogram to 
investigate the effects of myocardial infarction. A peripheral 
blood smear was sent for finding stomatocytes. She underwent 
autonomic function tests to rule out an involvement of the car-
diac autonomic system. It was required an eye examination to 
search for corneal opacities. Muscle biopsy was performed for 
histopathological characterization and skin punch biopsy for the 
study of small fibers. Biopsies were taken after local anesthesia 
using a 3-mm disposable. Three sections randomly chosen from 
1 http://www.hgmd.cf.ac.uk/ac/gene.php?gene=ABCA1. 
each biopsy were immunoassayed with polyclonal anti-protein-
gene-product 9.5 (PGP 9.5) antibodies using the free-floating 
protocol for bright field immunohistochemistry. The linear 
epidermal nerve fiber (ENF) density was calculated according to 
the guidelines given by the European Federation of Neurological 
Societies (21).
Cerebral, brainstem, and medullar MRI showed only a 
chronic vascular encephalopathy. Abdomen US evidenced a 
finely compact liver echostructure, angiomyolipoma in the left 
kidney, and aortic intimal medial increase in thickness with 
atheroma, without visceromegaly. Echocardiogram evidenced a 
reduced global systolic function, with 44% ejection fraction, mild 
pulmonary hypertension (estimated PAPs 37 mmHg), and initial 
signs of dilated cardiomyopathy, as demonstrated by tetravalvu-
lar insufficiency. Peripheral blood smear showed red blood cell 
anisopoikilocytosis. Tilt test evidenced basal hypotension with 
adequate peripheral vascular sympathetic response and probably 
iatrogenic marked reduction in heart rate variability (patient is 
on beta-blockers following myocardial infarction). Eye examina-
tion showed two corneal leucomas in the right eye; a corneal 
disepithelization was demonstrated by fluorangiography. Muscle 
biopsy presented fiber II hypotrophy. Skin biopsy, performed in 
the territory of distribution of first trigeminal branch, D5 der-
matome and thigh, showed a wide reduction in intraepidermal 
innervations (Figure  1), 1.6, 0, and 4.3/mm, respectively, thus 
explaining the pseudosyringomyelic pattern found.
Family study
AC family tree is shown in Figure  2A. Her parents were first-
degree cousins. She is the fifth of six siblings. One brother 
was born dead; one brother was dead 2 days after his birth for 
pneumonia. The oldest sister, DC, is 66 years old and reported a 
clinical history a myocardial infarction at age of 55 years, aortic 
and mitral valve replacement, essential hypertension, and hands 
osteoarticular deformities. The second sister, CC, is 64 years old 
and presents a non-specified cardiac valve replacement and lower 
limbs paresthesia. The brother, RC, is 52 years old and presents 
mild-moderate mitral valve insufficiency, mild tricuspid valve 
insufficiency, and severe hypoesthesia for pain in his upper limbs 
(he burned his arm without feeling pain). DC presents clinical 
findings similar to AC. CC has deficit of strength only in orbicula-
ris oris and hypoesthesia for temperature in her upper limbs. RC 
presents reduction of strength in orbicularis oris, left foot-drop, 
and hypoesthesia for pain in upper limbs.
electrophysiological Findings
AC presented a definite demyelinating neuropathy, as defined 
by EFNS criteria (22), with secondary axonal loss. Amplitude, 
latencies, and conduction velocities of different explored nerves 
are summarized in Table 1. Distal right ulnar cMAP presented a 
temporal dispersion and a slow conduction velocity in the under 
elbow–wrist and above elbow–under elbow tract, with absence 
of F wave, and presence of multiple A waves. F wave from right 
median was absent. Left median presented temporal dispersion 
in elbow–wrist and ERB point–elbow tracts. EMG showed 
neurogenic potentials and deficit in spatial recruitment in right 
extensor carpi, bilateral orbicularis oris, and right first digital 
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FIGURe 2 | (a) Pedigree of TD family. Squares indicate male family members and circles female family members. Slashes indicate deceased people and arrows 
indicate proband. Roman numerals to the left of the pedigree indicate the generation; numerals to the upper left of each symbol indicate the individual family 
member. Filled symbols indicate homozygotes and half-filled symbols heterozygotes for the Y1698X mutation in the ABCA1 gene. The columns under each symbol 
indicate, from top to bottom, the total cholesterol, triglycerides, LDL, and HDL-C concentration (mg/dl). (B) Electropherograms reporting nucleotide change in 
carriers of Y1698X mutation in the ABCA1 gene. Horizontal gray marks under electropherograms indicate the reading frame of codon interested by the mutation.  
(C) Wild type and prediction of Y1698X mutation on the structure of ABCA1 protein. nd, not detectable.
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interosseous (FDI), where fibrillation potentials were detected. 
She also underwent LASER evoked potentials in order to inves-
tigate small fibers: normal from right thigh, no signal from right 
D5 (LASER anesthesia) and right V1.
DC showed absence of SNAP from bilateral sural and ulnar 
nerves and low cMAP amplitude in bilateral plantar medial and 
ulnar at motor ENG exam.
Moreover, ulnar nerves presented temporal dispersion in the 
under elbow–wrist tract and a slow conduction velocity with 
delay in F waves. EMG showed neurogenic potentials and deficit 
in spatial recruitment in right anterior tibial, bilateral FDI, and 
bilateral orbicularis oris.
CC presented normal SNAP, cMAP, and NCV from examined 
nerves. EMG showed neurogenic potentials in bilateral FDI.
taBLe 1 | electrophysiological findings in tD family members.
DC CC aC RC Control 
values
R L R L R L R L
sNC
SCV (m/s)
Sural Abs Abs 53.8 50.0 52.4 50.0 48.0 45.0 >39.5
Ulnar Abs Abs 50.0 50.0 Abs 54.5 50.0 55.0 >47.0
Median – – 57.5 60.0 Abs 44.4 48.0 50.0 >49.2
Radial – – 60.0 66.0 Abs 26.0 60.0 75.0 >45.0
SNAP (μV)
Sural Abs Abs 28.4 21.4 12.6 8.3 2.4 7.1 >6.3
Ulnar Abs Abs 8.4 10.9 Abs 3.6 4.8 5.6 >7.5
Median – – 14.6 11.2 Abs 2.8 9.8 8.2 >15.8
Radial – – 49.9 54.0 Abs 13.7 7.1 20.1 >23.5
MNC
DML (ms)
Medial plantar 5.3 5.7 3.2 3.7 3.9 4.2 3.9 5.1 <4.8
Peroneal – – 4.4 3.2 3.2 2.9 4.2 5.6 <4.5
Ulnar 4.5 4.8 2.8 2.8 5.7 1.8 2.4 2.3 <2.8
Median – – 2.4 3.9 6.1 4.2 4.2 3.7 <3.2
Facial 3.0 3.1 2.9 2.9 2.4 2.9 2.7 2.9 <2.1
MCV (m/s)
Medial plantar n.d. n.d. 47.1 54.0 45.7 50.0 45.0 47.0 >40.3
Peroneal – – 51.0 45.5 47.9 44.9 40.0 39.0 >42.5
Ulnar 26.1 25.2 59.0 61.0 30.0 43.5 55.0 50.0 >50.4




0.1/n.d. 0.3/n.d. 6.4/4.9 8.6/7.7 5.7/4.7 7.4/4.9 13.1/7.8 12.5/7.8 >8.7
Peroneal  
(A/UCF/ACF)
– – 9.7/9.7/9.2 7.8/5.8/5.6 6.1/4.6/5.0 6.1/5.1/4.7 3.5/3.5/3.5 1.2/1.1/1.1 >3.4
Ulnar  
(W/UE/AE/EP)
3.4/2.2/–/– 2.3/1.5/–/– 16.6/16.6/13.2/12.8 12.5/12.6/12.0/12.0 0.4/0.3/0.3/0.3 6.6/6.6/6.6/4.3 11.1/9.0/7.4/7.4 7.8/7.4/7.2/7.2 >8.3
Median (W/E/EP) – – 14.3/14.5/13.4 6.1/6.0/6.0 0.3/0.3/0.3 1.8/1.8/1.8 5.3/4.5/4.3 4.2/3.3/3.3 >9.0
Facial 0.1 0.2 1.8 2.0 0.8 0.5 0.5 0.8 >1.8
R, right; L, left, –, not done, n.d., not detectable; Abs, Absent; SNC, sensory nerve conduction; SCV, sensory conduction velocity; SNAP, sensory nerve action potential; MNC, 
motor nerve conduction; DML, distal motor latency; MCV, motor conduction velocity; Cmap, compound motor action potential; W, wrist; UE, under the elbow; AE, above the elbow; 
E, elbow, EP, Erb point; A, ankle; K, knee; UCF, under the caput fibulae; ACF, above the caput fibulae.
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RC presented a mild diffuse reduction of sensory and motor 
nerves amplitude of explored nerves, with a temporal dispersion 
in the under caput fibulae–ankle tract and absence of F-wave 
in left deep peroneal. EMG showed neurogenic potentials from 
tibialis anterior bilaterally, right medial gastrocnemius, left vas-
tus lateralis, and right FDI. He also underwent LASER evoked 
potentials in order to investigate small fibers: normal from right 
thigh, increase in cortical latency from right D10 dermatome; no 
cortical signal from right D8 (LASER anesthesia).
skin Biopsy
Skin biopsy was performed in DC from proximal and distal 
lower limb and in CC from proximal and distal upper limb. DC 
presented a wide reduction in intraepidermal innervations (6.3/
mm from proximal site; 0.3/mm from distal site). CC presented 
normal intraepidermal innervations (12.4/mm from proximal 
site; 10.9/mm from distal site).
Laboratory assessment
AC, DC, and RC presented almost undetectable HDL choles-
terol (HDL-C) and extremely low Apolipoprotein A1 levels in 
their plasma (Table  2). CC, though not presenting very low 
HDL-C, had low Apolipoprotein A1 levels. AC had low total 
and LDL cholesterol (LDL-C), but she was in therapy with 
statin. DC also presented hypertriglyceridemia. Other blood 
tests were normal.
The clinical history, together with objective and electrophysi-
ological findings and plasma lipid assessment, suggested diagno-
sis of TD. Therefore, a genetic test was requested.
Mutational analysis of aBCa1 Gene
We resequenced the ABCA1 gene; genomic DNA was extracted 
from peripheral blood leukocytes by the QIAamp Blood DNA 
kit (Qiagen, Hilden, Germany). The promoter, 50 exons and 
exon–intron junctions of the ABCA1 gene were PCR-amplified 
taBLe 2 | plasma lipid values in tD family members.
DC aC CC RC Reference values
Genotype Hom Hom Het Hom
Total cholesterol (mg/dl) 126 60 174 100 145–199
HDL (mg/dl) n.d. n.d. 44 n.d. >45
LDL (mg/dl) 88 38 107 75 <129
Triglycerides (mg/dl) 334 93 115 119 40–200
Apolipoprotein A1 (mg/dl) n.d. 24 115 n.d. >129
Apolipoprotein B (mg/dl) 121 64 100 104 60–117
n.d., not detectable; Hom, homozygous; Het, heterozygous.
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and sequenced by primers as reported (23) PCR reactions were 
performed in a total volume of 15  μl with 50  ng of genomic 
DNA, 6  pmols of each primer, 0.25 units of GoTaq hot start 
polymerase (Promega, Fitchburg, WI, USA), 175  μM of each 
dNTP (Fermentas, Waltham, MA, USA), 1.5 mM MgCl2 and 1× 
manufacturer’s buffer. The PCR cycle was the following: 2′ 95°C; 
35 cycles of 45″ 94°C, 1′ 30″ 58°C, 2′ 30″ 72°C followed by 7′ 
72°C. PCR products were purified by a common protocol based 
on thermosensitive alkaline phosphatase (Fermentas, Waltham, 
MA, USA) and exonuclease (USB Corporation, Cleveland, OH, 
USA). Sequencing reactions were performed by using the Big Dye 
Terminator Reaction Kit version 1.1 (Applied Biosystems, Foster 
City, CA, USA) according to the manufacturer’s instructions. 
Sequencing products were purified by Montage SEQ96 sequenc-
ing reaction cleanup kit (Millipore, Billerica, MA, USA) following 
manufacturer’s instructions and subsequently analyzed by the 
genetic analyzer ABI PRISM 3130xl (Applied Biosystems, Foster 
City, CA, USA). The sequence data were analyzed by using the 
software SeqScape (Applied Biosystems, Foster City, CA, USA) 
personalized for the semiautomatic recognition of sequence vari-
ations possibly found in the studied zones.
For the analysis of human ABCA1 cDNA and protein, the 
GenBank NM_005502.3 and NP_005493.2 were respectively 
used. The in  silico prediction of the effect of functionally 
uncharacterized sequence variations found in the proband was 
performed, depending on the kind of sequence variation, using 
the following software: PolyPhen-2,2 SIFT,3 automated splice 
site analysis,4 NetGene2,5 GeneMark,6 TESS,7 TFBIND,8 and 
TFsearch.9 In particular, the in  silico prediction of truncated 
protein was obtained by the ExPASY Translate tool.10
The novel mutation found was labeled according to the Human 
Genome Variation Society (DNA level; protein level)11.
The resequencing of ABCA1 in the proband evidenced 
the mutation c.5094C >  A p.Tyr1698* (legacy name Y1698X) 











in the exon 37 of ABCA1 gene. It was expected to generate a 
truncated protein, missing the last four intramembrane repeats 
(Figure 2C). This mutation was found in homozygosity in DC 
e RC and in heterozygosity in CC (Figure 2A). In addition, this 
mutation was also found in heterozygosity in the two sons of 
DC and AC. In the proband, also several polymorphisms and 
functionally uncharacterized sequence variations were found. 
The in silico analysis of these variations evidenced that they were 
benign.
DIsCUssIoN
In this report, we describe a family characterized by a familial 
HDL deficiency (FHD), with a novel homozygous nonsense 
mutation in the ABCA1 gene. Mutation analysis predicted the 
synthesis of a truncated protein (Figure 2C). Neurological symp-
toms represented the prevalent clinical sign in the proband. It has 
been reported that several different inherited defects involving 
the apolipoprotein (APO)AI, ABCA1, or lecithin:cholesterol 
acyl transferas (LCAT) genes may be responsible for FHD (24). 
Also APOA1-related amyloidosis is characterized by a small fiber 
neuropathy. However, the presence of neurological symptoms 
associated with history of tonsillectomy and myocardial infarc-
tion, but not of kidney function impairment (which is typical of 
LCAT-associated FHD) nor cardiomyopathy [which is typical 
of APOA1-related amyloidosis – (25)] should point toward the 
diagnosis of ABCA1-associated TD.
The clinical phenotype of AC was peculiar being character-
ized by a syringomyelic-like anesthesia with electrophysiological 
findings of a demyelinating neuropathy with secondary axonal 
loss and small fibers involvement. In DC, AC, and RC both 
pseudosyringomyelic and demyelinating patterns were found. 
Concerning the pseudosyringomyelic pattern, spinal MRI did not 
show any medullar cavities in AC, as described by other Authors 
(14). Schmalbruch et al. (26) demonstrated loss of small spinal 
ganglion cells in light and electron microscopy. In our patients, 
LEP and skin biopsy confirmed this data, showing a global reduc-
tion in ENF density; in AC, no small fiber was found in dorsal 
dermatome (D5), thus partially explaining the pseudosyringo-
myelic pattern. It has been proposed that lipid accumulation and 
fiber loss may be detected in peripheral nerves, but much more 
important in dorsal roots and sensory nerves, assuming the form 
of a primary neuronopathy with secondary axonal degeneration 
(27–30). As proposed by Zuchner et al. (28), this phenomenon 
could not be ascribed to impaired lipid efflux from Schwann 
cell and attributed to other ABCA1 substrates, thus explaining 
mutation-specific differences.
Complications of peripheral neurological system are a rather 
common feature of TD (13). To date, seven different mutations 
in ABCA1 have been characterized in neuropathic or pseudo-
syringomielic cases of TD (28, 30, 31). They have been located 
in different regions of the gene, but have in common to leading 
to premature termination of ABCA1 translation and the nearly 
total absence of ABCA1 protein. It is noteworthy that also the 
novel variant reported in our family is a nonsense truncating 
mutation, even though it is located on exon 37, thus expecting 
to generate a longer truncated protein, missing only the last 
FIGURe 3 | Colon biopsy with foamy histiocytes (a) 10×, (B) 20×, and (C) 40×.
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